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Nlrp3 inflammasome activation occurs in response
to numerous agonists but the specific mechanism
by which this takes place remains unclear. All pre-
viously evaluated activators of the Nlrp3 inflam-
masome induce the generation of mitochondrial
reactive oxygen species (ROS), suggesting a model
in which ROS is a required upstream mediator of
Nlrp3 inflammasome activation. Here we have identi-
fied the oxazolidinone antibiotic linezolid as a Nlrp3
agonist that activates the Nlrp3 inflammasome inde-
pendently of ROS. The pathways for ROS-dependent
and ROS-independent Nlrp3 activation converged
upon mitochondrial dysfunction and specifically
the mitochondrial lipid cardiolipin. Cardiolipin bound
to Nlrp3 directly and interference with cardiolipin
synthesis specifically inhibited Nlrp3 inflammasome
activation. Together these data suggest that mito-
chondria play a critical role in the activation of the
Nlrp3 inflammasome through the direct binding of
Nlrp3 to cardiolipin.
INTRODUCTION
The Nlrp3 inflammasome is a multiprotein complex consisting
of the nucleotide-binding domain leucine-rich repeat containing
(NLR) family member Nlrp3, the adaptor protein ASC, and
the cysteine protease caspase-1 (Agostini et al., 2004). The
Nlrp3 inflammasome can activate caspase-1 in response to
cellular danger resulting in the processing and secretion of the
proinflammatory cytokines IL-1b and IL-18 (Kanneganti et al.,2006; Mariathasan et al., 2006; Martinon et al., 2006; Sutterwala
et al., 2006). A diverse array of stimuli can activate the Nlrp3
inflammasome including both pathogen-associated molecular
patterns (PAMPs) and endogenous host-derived molecules
indicative of cellular damage. The divergent qualities of the
Nlrp3 inflammasome agonists have led to the supposition that
the activators converge on a common pathway with a final
endogenous ligand activating Nlrp3. An attribute that many
activators of the Nlrp3 inflammasome share is their ability to
generate reactive oxygen species (ROS). Interruption of ROS
production with pharmacological inhibitors blocks activation
of the Nlrp3 inflammasome, suggesting that the generation of
ROS is a required upstream event for Nlrp3 activation (Cassel
et al., 2008; Cruz et al., 2007; Dostert et al., 2008; Pe´trilli et al.,
2007; Zhou et al., 2011). Recent studies have elucidated the
cellular source of the responsible ROS to be of mitochondrial
origin and independent of the NADPH oxidases (Meissner
et al., 2008; Nakahira et al., 2011; van Bruggen et al., 2010;
Zhou et al., 2011).
Linezolid belongs to the oxazolidinone class of antibiotics
and has been employed in the treatment of infections caused
by antibiotic-resistant bacteria, including vancomycin-resistant
enterococcus and methicillin-resistant Staphylococcus aureus
(Ament et al., 2002), and as part of multidrug regimens in the
treatment of mycobacterial infections (Sood et al., 2006). A
number of infections associated with these pathogens, such as
endocarditis and osteomyelitis, require antibiotic therapy for up
to 8 weeks or more. This prolonged duration of therapy can
be problematic because linezolid has been associated with
myelosuppression at rates as high as 32% of patients receiving
this antibiotic (Attassi et al., 2002; Dawson et al., 2005). Although
the mechanism underlying linezolid-induced myelosuppression
remains undefined, mitochondrial toxicity has been implicated
in this process (De Vriese et al., 2006; McKee et al., 2006;
Soriano et al., 2005).Immunity 39, 311–323, August 22, 2013 ª2013 Elsevier Inc. 311
Figure 1. Linezolid Induces Caspase-1-Dependent IL-1b Secretion
(A) J774A.1 mouse macrophages were stimulated with either linezolid or LPS; culture supernatants were collected 18 hr later and TNF-a and IL-6 release were
measured by ELISA.
(B) LPS-primed J774A.1 macrophages were stimulated with either silica or linezolid; culture supernatants were collected 18 hr later and IL-1b release was
measured by ELISA.
(C) LPS-primed J774A.1 macrophages were stimulated with linezolid or silica; culture supernatants were collected at the indicated times and cytotoxicity
measured by LDH release and expressed as a percentage of LDH release by Triton X-100 detergent.
(D) LPS-primed human PBMCs were incubated with 20 mM z-YVAD-fmk for 1 hr prior to the addition of silica or linezolid. 18 hr after stimulation, culture su-
pernatants were collected and IL-1b release measured by ELISA.
(E) LPS-primed J774A.1 macrophages were challenged with silica or 1, 10, or 100 mg/ml of the indicated antibiotic for 18 hr; IL-1b release into the culture su-
pernatant was measured by ELISA.
Determinations were performed in triplicate and expressed as the mean ± SD. Results are representative of two separate experiments. See also Figure S1.
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Nlrp3 Inflammasome Activation through CardiolipinIn this study we demonstrate that linezolid was capable of
activating the Nlrp3 inflammasome. Activation of the Nlrp3
inflammasome by linezolid resulted in an in vivo inflammatory
response with associated suppression of bonemarrow erythroid
precursors, consistent with the hematologic anomalies seen in
patients that have been ascribed to direct effects of linezolid
on mitochondria. In contrast to other activators of the Nlrp3
inflammasome, linezolid-induced activation occurred in a
ROS-independent manner. However, activation of the Nlrp3
inflammasome by linezolid and all other Nlrp3 agonists tested
was inhibited by mitochondrial stabilization with cyclosporine
A. We further confirm the central role of the mitochondria in
Nlrp3 activation by demonstrating that Nlrp3 binds to a mito-
chondrial phospholipid in a stimulus-dependent manner, which
we have identified as the mitochondrial-specific phospholipid
cardiolipin. In addition, the disruption of the cardiolipin synthesis
pathway results in impaired Nlrp3 inflammasome activation,
and the addition of cardiolipin (but not other phospholipids) to
a broken cell system triggers caspase-1 activation. The finding
of an ROS-independent pathway to Nlrp3 inflammasome acti-
vation, the requirement for cardiolipin in this process, and its312 Immunity 39, 311–323, August 22, 2013 ª2013 Elsevier Inc.direct binding to Nlrp3 sheds light on the mechanism by which
the Nlrp3 inflammasome is activated and suggests that mito-
chondrial disruption and the resultant binding of cardiolipin to
Nlrp3, and not ROS per se, is ultimately responsible for Nlrp3
inflammasome activation.
RESULTS
Linezolid Induces the Secretion of IL-1b
but Not TNF-a or IL-6 In Vitro
The mechanism by which linezolid induces myelosuppression
has not been elucidated. Because inflammatory mediators
have both positive and negative effects on myeloid and
erythroid precursors, we asked whether linezolid was capable
of inducing an inflammatory response in vitro. Because blood
concentrations of linezolid in humans after oral administration
of 600 mg of linezolid reach peak concentrations of approxi-
mately 16.3–21 mg/ml (MacGowan, 2003), we used doses of
1, 10, 100, and 200 mg/ml for our in vitro stimulation. In contrast
to LPS, linezolid was a poor inducer of TNF-a and IL-6 produc-
tion by the murine macrophage J774A.1 cell line (Figure 1A).
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Nlrp3 Inflammasome Activation through CardiolipinHowever, treatment of LPS-primed macrophages with linezolid
at the clinically relevant dose of 10 mg/ml as well as the slightly
higher dose of 100 mg/ml resulted in the secretion of IL-1b in a
dose-dependent manner (Figure 1B). Linezolid alone did not
induce IL-1b secretion (Figure S1A available online), consistent
with the actions of other stimuli of the inflammasome such as
silica and ATP that require prior macrophage priming in order
to activate caspase-1 (Cassel et al., 2008; Mariathasan et al.,
2006; Sutterwala et al., 2006). In addition, linezolid-induced
secretion of IL-1b occurred rapidly with maximal secretion
by 6 hr after challenge (Figure S1B). Recent studies have
demonstrated that necrotic cells are capable of inducing
macrophage inflammasome activation (Ghiringhelli et al.,
2009; Iyer et al., 2009). To ensure that the IL-1b secretion
observed was not secondary to linezolid-induced cytotoxicity,
we assessed the degree of cell death in macrophages after
linezolid treatment by measuring lactate dehydrogenase (LDH)
release as a marker of cellular damage. LDH release at 6 hr
after linezolid treatment suggested less than 10% cell death,
by which time maximal IL-1b release had already been
achieved (Figure 1C). This low induction of cell death with
Nlrp3 inflammasome activation was confirmed by propidium
iodide staining (Figure S1C). Linezolid was also capable of
inducing IL-1b secretion from human peripheral blood mono-
nuclear cells (PBMCs) and the human monocytic THP-1 cell
line via a mechanism that was inhibited by the caspase-1 inhi-
bitor z-YVAD-fmk (Figures 1D and S1D). Collectively, these
results demonstrate that linezolid was capable of inducing the
caspase-1-dependent secretion of IL-1b from both human
PBMCs and mouse macrophages.
Linezolid inhibits bacterial protein synthesis by binding to
the bacterial 23S ribosomal RNA of the 50S subunit and prevent-
ing a functional 70S initiation complex from forming, which is
essential for the bacterial translation process. To determine
whether other antibiotics were capable of inducing IL-1b
secretion, we challenged J774.A1 macrophages with selected
antibiotics from multiple different classes of antimicrobials,
including those that target protein synthesis as their mechanism
of action. Only gramicidin induced substantial IL-1b secretion
from macrophages (Figures 1E and S1E), partially consistent
with previous studies (Allam et al., 2011; Walev et al., 1995).
Similar to linezolid, the antibiotic chloramphenicol targets mito-
chondrial ribosomes but was incapable of activating the Nlrp3
inflammasome (Figure S1F). Based on these data, the capacity
of linezolid to trigger IL-1b secretion was not shared by antibi-
otics with similar mechanisms of antibacterial action, but rather
was a property unique to linezolid.
Linezolid Induces Nlrp3-Dependent Inflammatory
Responses In Vitro and In Vivo
To determine whether the Nlrp3 inflammasome was involved in
linezolid-induced IL-1b secretion, we challenged LPS-primed
bone marrow-derived macrophages (BMDMs) from wild-type
(WT) and from Nlrp3-, ASC-, caspase-1-, and Nlrc4-deficient
mice with linezolid in vitro. Nlrp3-, ASC-, and caspase-1-defi-
cient BMDMs displayed a marked defect in their ability to pro-
cess and secrete IL-1b in response to linezolid compared to
WT BMDMs (Figure 2A). In contrast, BMDMs deficient in Nlrc4,
which is required for caspase-1 activation in response to cyto-solic flagellin and PrgJ, a component of the bacterial type III
secretion system (Sutterwala and Flavell, 2009), secreted IL-1b
in response to linezolid (Figure 2A).
Caspase-1 activation involves autocatalytic processing of the
45 kDa pro-caspase-1 to generate two subunits, p20 and p10.
Caspase-1 activation in LPS-primed WT BMDMs stimulated
with linezolid was detected in immunoblots by the appearance
of the p10 cleavage product (Figure 2B). Caspase-1 activation
in response to linezolid in Nlrp3- or ASC-deficient LPS-primed
BMDMs was not observed (Figure 2B). Taken together
these findings suggest that linezolid was capable of inducing
caspase-1-mediated IL-1b secretion in a manner dependent
on the Nlrp3 inflammasome.
To examine whether the Nlrp3 inflammasome was involved
in the inflammatory response to linezolid in vivo, we injected
linezolid intraperitoneally into WT and into Nlrp3-, ASC-, or
caspase-1-deficient mice (Figure 2C). At 16 hr after challenge
with linezolid, influx of neutrophils into the peritoneal cavity
of WT mice was markedly greater than mice that received the
control buffer D5W (5% dextrose in water). This neutrophil
influx was significantly diminished in mice deficient in com-
ponents of the Nlrp3 inflammasome, suggesting that the in vivo
inflammatory response to linezolid was also dependent upon
the Nlrp3 inflammasome (Figure 2C).
Linezolid therapy is associated with myelosuppression
(Attassi et al., 2002; Dawson et al., 2005; Gerson et al., 2002;
Taketani et al., 2009) and in particular with an increased
myeloid/erythroid cell ratio (Dawson et al., 2005; Green et al.,
2001; Taketani et al., 2009). We therefore examined myeloid
and erythroid precursors in the bone marrow of mice treated
with 200 mg/kg/day of linezolid for 12 days. Linezolid-treated
WT mice had significantly decreased mature erythroid cells
and increased myeloid cells compared to control animals (Fig-
ures 2D and 2E). In contrast, there was no difference observed
in either erythroid or myeloid cells in linezolid-treated Nlrp3/
mice compared to control animals (Figures 2D and 2E). These
data demonstrate that linezolid induced inflammatory responses
in vivo and that its effect on the bone marrow depended on
the Nlrp3 inflammasome. Hence the activation of the Nlrp3
inflammasome by linezolid may contribute to the in vivo toxicity
associated with linezolid therapy.
Linezolid-Mediated Activation of the Nlrp3
Inflammasome In Vitro Requires a Potassium Efflux
To gain mechanistic insights into how linezolid activated the
Nlrp3 inflammasome, we examined pathways required for
Nlrp3 inflammasome activation in response to other agonists.
Particulate agonists such as monosodium urate (MSU), silica,
and alum require internalization by the macrophage in order
to activate the Nlrp3 inflammasome (Cassel et al., 2008;
Eisenbarth et al., 2008; Martinon et al., 2006). Given linezolid’s
lipophilic nature that allows it to cross the cell membrane,
we predicted that its activation of the Nlrp3 inflammasome
would be independent of phagocytosis. Treatment of LPS-
primed J774A.1 macrophages with cytochalasin D, which
blocks actin polymerization, inhibited silica-induced, but not
ATP-mediated, IL-1b secretion as expected (Cassel et al.,
2008). Cytochalasin D did not inhibit linezolid from inducing
macrophage IL-1b secretion (Figure 3A). These dataImmunity 39, 311–323, August 22, 2013 ª2013 Elsevier Inc. 313
Figure 2. Linezolid Induces Nlrp3-Dependent Inflammation In Vitro and In Vivo
(A) LPS-primed BMDMs fromWT and Nlrp3-, ASC-, caspase-1-, or Nlrc4-deficient mice were stimulated with either linezolid or silica. Culture supernatants were
collected at 18 hr after stimulation and IL-1b release measured by ELISA.
(B) Lysates from LPS-primedWT and Nlrp3-, ASC-, or Nlrc4-deficient BMDMs stimulated with linezolid for 18 hr were immunoblotted with antibodies against the
p10 subunit of caspase-1.
Determinations were performed in triplicate and expressed as the mean ± SD. Results are representative of four (A) and three (B) separate experiments.
(C) WT and Nlrp3-, ASC-, and caspase-1-deficient mice (n = 5) were challenged with 200 mg/kg of linezolid intraperitoneally; 16 hr later neutrophil influx into the
peritoneum was determined. Control WT mice (n = 3) were challenged intraperitoneally with D5W. Results are representative of at least three independent
experiments. *p < 0.01 by two-tailed Mann-Whitney test.
(D and E) WT and Nlrp3-deficient mice received daily intraperitoneal injections of linezolid (200 mg/kg) (WT, n = 9; Nlrp3/, n = 9) or an equal volume of control
D5W (WT, n = 10; Nlrp3/, n = 6). After 12 days, femurs were sectioned and stained with H&E.
(D) Representative 6003 images are shown. Open arrows indicate myeloid cells and black arrows represent erythroid cells.
(E) Themature stages of myeloid and erythroid cells were counted in each section with two sections counted per femur. Results are pooled from two independent
experiments and expressed as the mean ± SEM. *p < 0.01 by two-tailed Mann-Whitney test.
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Nlrp3 Inflammasome Activation through Cardiolipindemonstrate that, as predicted by its molecular structure,
active phagocytosis of linezolid is not required for Nlrp3 inflam-
masome activation.
The cell surface receptor P2RX7 has been implicated in
Nlrp3 inflammasome activation in response to extracellular
ATP (Solle et al., 2001). Linezolid-mediated IL-1b secretion
remained intact in the absence of the P2RX7 (Figure 3B), sug-
gesting that P2RX7 was not required for linezolid-induced
inflammasome activation. Additionally, this finding suggests
that linezolid-induced Nlrp3 inflammasome activation was not
secondary to ATP release from damaged cells, as has been
observed for the chemotherapeutic agent doxorubicin (Ghiring-
helli et al., 2009).314 Immunity 39, 311–323, August 22, 2013 ª2013 Elsevier Inc.A common step required by all knownNlrp3 agonists to induce
caspase-1 activation is the efflux of cellular potassium (Pe´trilli
et al., 2007). Preventing the potassium efflux by increasing
extracellular potassium concentrations inhibits caspase-1 acti-
vation in response to stimuli that activate Nlrp3. Consistent
with this, increased extracellular potassium significantly in-
hibited linezolid-induced IL-1b secretion from LPS-primed
J774A.1 macrophages (Figure 3C). As expected, increased
extracellular potassium also inhibited Nlrp3-dependent silica-
induced, but not AIM2-dependent Francisella tularensis LVS-
induced, IL-1b production (Figure 3C). Hence linezolid, like all
other known Nlrp3 stimuli, required a cellular potassium efflux
to induce macrophage IL-1b secretion.
Figure 3. Linezolid-Induced IL-1b Secretion Requires a Potassium
Efflux
(A) LPS-primed J774A.1 macrophages were incubated with 20 mM cytocha-
lasin D for 30 min prior to the addition of linezolid, silica, or ATP. 18 hr later,
culture supernatants were collected and IL-1b release measured by ELISA.
(B) LPS-primed WT and P2rx7/ BMDMs were stimulated with linezolid,
silica, or ATP. 18 hr after stimulation, culture supernatants were collected and
IL-1b release measured by ELISA.
(C) LPS-primed J774A.1 macrophages were incubated in either high Na+ or
high K+ containing media and then stimulated with either linezolid, silica, or
Immunity
Nlrp3 Inflammasome Activation through CardiolipinLinezolid-Induced Nlrp3 Inflammasome Activation Is
Independent of ROS but Inhibited by Mitochondrial
Stabilization with Cyclosporine A
ROS generation has been suggested to be an absolute require-
ment for activation of the Nlrp3 inflammasome (Dostert et al.,
2008; Martinon, 2010; Tschopp and Schroder, 2010), and two
recent studies have shown that this ROS is of mitochondrial
origin (Nakahira et al., 2011; Zhou et al., 2011). To examine
the role of ROS in linezolid-induced Nlrp3 inflammasome acti-
vation, we utilized pharmacologic inhibitors of ROS. Macro-
phages were pretreated with the antioxidant N-acetylcysteine
(NAC), the flavoprotein inhibitor diphenylene iodonium (DPI),
or the metabotropic glutamate receptor 3 agonist (2R,4R)-4-
aminopyrrolidine-2,4-dicarboxylate (APDC) prior to challenge
with either linezolid, silica, nigericin, ATP, or alum. A recent study
suggests that treatment with ROS inhibitors blocks priming of
the Nlrp3 inflammasome (Bauernfeind et al., 2011); in order to
specifically examine the effects of ROS on activation rather
than priming of the Nlrp3 inflammasome, we treated cells with
DPI, NAC, or APDC after LPS priming but prior to the addition
of Nlrp3 agonists. As previously observed (Cassel et al., 2008;
Cruz et al., 2007; Dostert et al., 2008; Pe´trilli et al., 2007; Zhou
et al., 2011), the ROS inhibitors NAC, DPI, and APDC blocked
silica-, nigericin-, ATP-, and alum-induced IL-1b secretion and
caspase-1 activation when given after LPS priming (Figures 4A
and 4B). Unexpectedly, NAC, DPI, and APDC all failed to inhibit
linezolid-induced IL-1b secretion (Figure 4A). Caspase-1 activa-
tion induced by linezolid was also not inhibited by DPI treatment
(Figure 4B). To more closely examine the effect of inhibition of
mitochondria-derived ROS, we treated macrophages with the
mitochondria-targeted antioxidant Mito-TEMPO prior to expo-
sure to agonists. As shown previously, Mito-TEMPO inhibited
ATP-mediated IL-1b secretion and caspase-1 activation (Figures
4C and 4D; Nakahira et al., 2011). Consistent with the data in
Figure 4A, Mito-TEMPO failed to suppress linezolid-induced
IL-1b secretion and caspase-1 activation (Figures 4C and 4D).
Similarly, inhibition of the mitochondrial respiratory chain with
antimycin A or rotenone blocked IL-1b induced by the ROS-
dependent activators ATP and silica but had no effect on release
of IL-1b induced by linezolid (Figure 4E). These data suggest
that the generation of mitochondrial ROS is not required for
linezolid to activate the Nlrp3 inflammasome. We next asked
whether linezolid was capable of inducing mitochondrial ROS
generation. As expected, the treatment of macrophages with
ATP resulted in ROS generation as demonstrated by a shift in
MitoSOX fluorescence; however, treatment with linezolid had
minimal effect on mitochondrial ROS generation in comparison
to untreated macrophages (Figure 4F). Taken together, these
data implicate a mechanism for linezolid-induced Nlrp3 inflam-
masome activation that is independent of ROS.
Linezolid has been implicated in the inhibition of mitochondrial
protein synthesis; both the amount and activity of mitochondrial
respiratory-chain complexes are decreased in animals and
patients receiving linezolid, thereby supporting the suspicionF. tularensis LVS (MOI 50:1). After 18 hr, culture supernatants were collected
and IL-1b release measured by ELISA.
Determinations were performed in triplicate and expressed as the mean ± SD.
Results are representative of three (A) and two (B andC) separate experiments.
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Figure 4. Linezolid-Induced Nlrp3 Inflammasome Activation Is Independent of ROS Generation
(A) LPS-primed J774A.1 macrophages were pretreated with the ROS inhibitors DPI (20 mM), APDC (20 mM), or NAC (1 mM) for 30 min prior to stimulation with
linezolid, silica, nigericin, ATP, or alum. 18 hr later, supernatants were collected and IL-1b secretion measured by ELISA.
(B) Lysates from LPS-primed J774A.1 macrophages challenged with linezolid or silica in the absence or presence of DPI were immunoblotted with antibodies
against the p10 subunit of caspase-1.
(C) LPS-primed J774A.1 macrophages were pretreated with the antioxidant Mito-TEMPO (500 mM) for 1 hr prior to stimulation with linezolid or ATP. 18 hr later,
supernatants were collected and IL-1b secretion measured by ELISA. *p = 0.003 by two-tailed unpaired Student’s t test.
(D) Lysates from LPS-primed J774A.1 macrophages challenged with linezolid or ATP in the absence or presence of Mito-TEMPO were immunoblotted with
antibodies against the p10 subunit of caspase-1.
(E) LPS-primed J774A.1 macrophages were treated with antimycin A (5 mg/ml) or rotenone (4 mM) for 30 min prior to stimulation with ATP, linezolid, or silica.
Supernatants were collected after 12 hr and IL-1b secretion measured by ELISA.
(F) LPS-primed J774A.1macrophages were treated with ATP (5mM), linezolid (25 mg/ml), or media for 1 hr and then stained withMitoSOX red (2.5 mM) for the final
15 min of the stimulation.
(G) LPS-primed J774A.1 cells were pretreated with 20 mMCsA for 1 hr and then challenged with linezolid, silica, or nigericin for 6 hr. Supernatants were collected
and cytokine secretions analyzed by ELISA. *p = 0.037, **p = 0.003 by two-tailed unpaired Student’s t test. Determinations were performed in triplicate and
expressed as the mean ± SD.
Results are representative of four (A, left panel; C), three (G), and two (A, right panel; B, D–F) separate experiments. See also Figure S2.
Immunity
Nlrp3 Inflammasome Activation through Cardiolipinthat linezolid has a deleterious effect on mitochondria (De Vriese
et al., 2006; McKee et al., 2006; Soriano et al., 2005). Consistent
with other Nlrp3 agonists that have been demonstrated to
induce mitochondrial dysfunction (Misawa et al., 2013; Zhou
et al., 2011), we found that linezolid also induced mitochondrial316 Immunity 39, 311–323, August 22, 2013 ª2013 Elsevier Inc.dysfunction as measured by diminished cellular ATP and
NAD+ production (Figures S2A and S2B). We also observed
diminished mitochondrial cytochrome c oxidase (complex IV)
activity in macrophages challenged with linezolid (Figure S2C).
To determine the effect of mitochondrial dysfunction on Nlrp3
Immunity
Nlrp3 Inflammasome Activation through Cardiolipininflammasome activation, we pretreated J774A.1 macrophages
with cyclosporine A, an inhibitor of mitochondrial membrane
permeability transition (MPT), before stimulation with ROS-
dependent and ROS-independent Nlrp3 activators. Inhibition
of MPT prevented the release of IL-1b, but not TNF-a, in
response to both classes of activators (Figure 4G), suggesting
that whereas ROS was not a prerequisite for activation of
Nlrp3 inflammasome by all agonists, the generation of MPT was.
Mitochondrial Cardiolipin Binds to Nlrp3
Previous studies have shown that Nlrp3 associates with the
mitochondria upon activation (Misawa et al., 2013; Zhou et al.,
2011). To determine which mitochondrial component binds to
Nlrp3, we radiolabeled cellular phospholipids via 14C-linoleic
acid and then treated macrophages with Nlrp3 agonists. Cells
were fractionated into cytosolic and mitochondrial fractions
and Nlrp3 was immunoprecipitated from the mitochondrial frac-
tion. The immunoprecipitated fraction was then subjected to
organic extraction, and the amount of radioisotope within the
organic phase, representing lipids pulled down with the Nlrp3
immunoprecipitation, was compared between control and
stimulated groups. Increased radioisotope was found in the
organic phase of cells in which the Nlrp3 inflammasome had
been activated with either ATP or silica, suggesting increased
mitochondrial lipid association with Nlrp3 (Figure 5A). These
data suggest that Nlrp3 associates with a mitochondrial phos-
pholipid upon macrophage stimulation with an Nlrp3 agonist.
To identify the phospholipid that was interacting with Nlrp3, we
subjected the immunoprecipitates produced in Figure 5A to
thin-layer chromatography. A marked increase in the mito-
chondrial-specific lipid cardiolipin was observed in Nlrp3 immu-
noprecipitates frommacrophages that had been stimulated with
either ATP or silica (Figure 5B).
Cardiolipin is a non-bilayer-forming phospholipid that in
eukaryotic cells is found exclusively in the inner mitochondrial
membrane. Its structure is unique because it consists of two
diacylated phosphatidyl groups joined by a glycerol bridge
(Osman et al., 2011). Cardiolipin has been shown to play a critical
role in the activation of caspase-8 and the final downstream
activation of caspase-3 in the extrinsic pathway of apoptosis.
Additionally, a recent study suggested overlap between the
activation of Nlrp3 and the induction of apoptotic cell death
(Shimada et al., 2012). To evaluate whether these pathways
were related, we stimulated macrophages with Nlrp3 inflam-
masome agonists or staurosporine, an inducer of the extrinsic
apoptotic pathway. We found that activation of the Nlrp3
inflammasome by silica, but not nigericin, in LPS-primed macro-
phages resulted in minimal activation of caspase-3 (Figure 5C).
Apoptosis induced by staurosporine, shown by the cleavage of
caspase-3, was not sufficient for activation of the Nlrp3 inflam-
masome in unprimed macrophages as shown by the absence
of cleaved caspase-1 and lack of IL-1b secretion (Figures 5C
and 5D). However, if macrophages were first primed with LPS,
there was modest release of IL-1b and activation of caspase-1
induced by staurosporine (Figures 5C and 5D). These data
suggest that the association of cardiolipin with Nlrp3 was not
due to coincident activation of apoptotic pathways.
To confirm that Nlrp3 directly interacts with the mitochon-
drial lipid cardiolipin, we examined the interaction of Nlrp3with phospholipids by using a protein-lipid overlay assay. HA-
tagged mouse Nlrp3 showed binding to cardiolipin and some
weaker interactionwith phosphatidic acid and 3-sulfogalactosyl-
ceramide (Figure 5E). In confirmation of the specificity of
binding to Nlrp3, we found that purified His-tagged human
Nlrp3 bound to cardiolipin in a protein-lipid overlay assay (Fig-
ure 5F), whereas neither His-tagged human TLR4 nor His-tagged
human Nlrc4 bound to cardiolipin (Figure 5F). A recent study
demonstrated that the phospholipid ceramide was capable of
activating the Nlrp3 inflammasome (Vandanmagsar et al.,
2011); to assess whether ceramide and the related molecule
sphingomyelin were capable of interacting with Nlrp3, we
employed the use of lipid-coated agarose beads. Consistent
with the results of the protein-lipid overlay assay, we observed
binding of His-tagged Nlrp3 to cardiolipin-coated beads (Fig-
ure 5G). In contrast, Nlrp3 did not show any increase in binding
to ceramide- or sphingomyelin-coated beads compared to
control agarose beads (Figure 5G).
To characterize the Nlrp3 domain responsible for the interac-
tion with cardiolipin, we examined the binding of Flag-tagged
Nlrp3 domain constructs (Mayor et al., 2007) to cardiolipin by
using the protein-lipid overlay assay. In addition to a full-length
Nlrp3 (Nlrp3.1-1036), these constructs consisted of Nlrp3 with
a truncated leucine-rich repeat (LRR) domain lacking the
carboxyl aspect (Nlrp3DLRR.1-719), the Pyrin domain alone
(PYD.1-95), the NACHT domain alone (NACHT.69-546), or a
portion of the LRR domain (LRR.535-719). Cardiolipin interacted
with both the full-length Nlrp3 construct (Nlrp3.1-1036), the LRR
domain of Nlrp3 (LRR.535-719), and Flag-tagged Nlrp3 with the
truncated LRR domain construct (Nlrp3DLRR.1-719), but not
with the NACHT (NACHT.69-546) or Pyrin (PYD.1-95) domains
(Figure 5H). These data suggest that the LRR region shared by
these three constructs was required for their interaction with
cardiolipin (Figure 5H). Consistent with these results, we found
that Flag-tagged full-length Nlrp3 (Nlrp3.1-1036), LRR domain
(LRR.535-719), and Nlrp3 with a truncated LRR domain
(Nlrp3DLRR.1-719) constructs, but not the NACHT (NACHT.69-
546) or Pyrin (PYD.1-95) domain, bound to cardiolipin-coated
beads (Figure S3). Together these data demonstrate that
through its LRR domain, Nlrp3 can interact directly with the
mitochondrial membrane lipid cardiolipin.
Cardiolipin Is Sufficient and Required
for Inflammasome Activation
Cardiolipin could be playing one of two roles in Nlrp3 inflamma-
some activation. It could be acting as a docking site to colocalize
Nlrp3 to its activating ligand, and it could also be providing
the activating signal itself. To assess whether the interaction
between Nlrp3 and cardiolipin could result in inflammasome
activation, we utilized a broken cell system. Cells were primed
with LPS and then disrupted by nitrogen cavitation. Non-cardio-
lipin-based liposomes had no effect on caspase-1 activation, but
the addition of cardiolipin-carrying liposomes resulted in the
dose-dependent activation of caspase-1 (Figure 6A).
To determine whether the interaction between cardiolipin and
Nlrp3 had biological relevance to inflammasome activation, we
interfered with cellular cardiolipin synthesis by two independent
methods. Treatment of cells with the saturated long chain fatty
acid palmitate (C16:0) has been shown to diminish cardiolipinImmunity 39, 311–323, August 22, 2013 ª2013 Elsevier Inc. 317
Figure 5. Cardiolipin Binds to Nlrp3
(A and B) J774A.1 cells were radiolabeled for 24 hr with 14C-linoleic acid (10 mCi); cells were then LPS primed and stimulated for 12 hr with ATP or silica.
The mitochondrial fraction was isolated and subjected to immunoprecipitation with anti-Nlrp3 antibody or isotype control antibody. Lipids associated with the
immunoprecipitates were extracted and quantified (A); lipids were subjected to 1-D HPTLC and the location of cardiolipin (CL) migration determined by running a
cardiolipin standard in parallel (B). Results are expressed as the mean ± SEM of three independent experiments; **p < 0.01, ***p < 0.001 by two-tailed unpaired
Student’s t test (A).
(C and D) LPS-primed BMDMs were treated with staurosporine, silica, or nigericin for 8 hr. Cell lysates and supernatants were collected and lysates assessed
for caspase-1 and caspase-3 via immunoblot (C) and supernatants for IL-1b via ELISA (D); determinations were performed in triplicate and expressed as
the mean ± SD.
(E) Lipid strips were incubated with lysates of RAW264.7 cells expressing HA-tagged mouse Nlrp3 or control buffer; strips were washed and developed with a
mouse anti-HA antibody.
(F) Lipid strips were incubated with 10 mg/ml of His-tagged human Nlrp3, Nlrc4, or TLR4; strips were then washed and developed with a mouse anti-His antibody.
(G) The indicated phospholipid-coated beads were incubated with 10 mg/ml of His-tagged Nlrp3; after washes, bound and unbound His tagged-Nlrp3 was
determined by immunoblotting with an anti-Nlrp3 antibody.
(H) Lipid strips were incubated with lysates of HEK293T cells expressing Flag-tagged full-length Nlrp3.1-1036 or truncation mutants Nlrp3DLRR.1-719,
PYD.1-95, NACHT.69-546, or LRR.535-719; strips were then washed and developed with a mouse anti-FLAG antibody.
Results are representative of two (C, E, F, H), three (B, G), or four (D) separate experiments. See also Figure S3.
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Nlrp3 Inflammasome Activation through Cardiolipinsynthesis in cardiomyocytes (Ostrander et al., 2001). By using
thin-layer chromatography, we confirmed that J774A.1 macro-
phages grown in serum-free media in the presence of palmitate
generated less cardiolipin than did control cells (Figures S4A and
S4B). Consistent with a previous study (Wen et al., 2011), we
observed that acutely challenging LPS-primed macrophages
with palmitate resulted in the secretion of IL-1b (data not shown).
However, LPS-primed macrophages grown in serum-free media
in the presence of palmitate had markedly diminished IL-1b318 Immunity 39, 311–323, August 22, 2013 ª2013 Elsevier Inc.secretion in response to the Nlrp3 agonists silica and ATP (Fig-
ure 6B). In contrast, palmitate treatment did not compromise
the production of TNF-a in response to LPS priming (Figure 6B),
the secretion of IL-1b in response to Pseudomonas aeruginosa,
an activator of the Nlrc4 inflammasome (Figure 6C), or the ability
of the mitochondria to generate ROS (Figure S4C). To determine
whether this inhibition was specific to palmitate, we cultured
macrophages in serum-free media in the presence of oleate
(C18:1), which does not interfere with cardiolipin synthesis
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Nlrp3 Inflammasome Activation through Cardiolipin(Ostrander et al., 2001). Oleate-treated macrophages retained
their ability to secrete IL-1b in response to silica, ATP, and line-
zolid (Figure S4D). Recent studies have implicated calcium flux
and cAMP as critical regulators of Nlrp3 inflammasome activa-
tion (Lee et al., 2012; Murakami et al., 2012; Rossol et al.,
2012; Zhong et al., 2013). Consistent with previous findings,
the adenylate cyclase inhibitor KH7 induced the secretion of
IL-1b from LPS-primed J774A.1 macrophages (Figure S4E;
Lee et al., 2012). However, palmitate treatment markedly dimin-
ished IL-1b secretion in response to KH7, suggesting that reduc-
tion of intracellular cAMP precedes the interaction of Nlrp3 with
cardiolipin. The generation of cAMP and calcium flux in response
to the Nlrp3 agonists silica and ATP remained intact in palmitate-
treated macrophages (Figures S4F and S4G).
To confirm that the inhibition of Nlrp3 inflammasome activa-
tion associated with palmitate treatment was due to interference
with cardiolipin synthesis, palmitate-treated and control-treated
cells were LPS primed and subjected to the broken cell system.
Addition of cardiolipin liposomes to broken palmitate-treated
cells restored caspase-1 activation (Figure 6D). Together, these
data suggest that palmitate treatment inhibited IL-1b secretion in
response to Nlrp3 agonists through diminished cardiolipin syn-
thesis and thus that the ability of cardiolipin to directly activate
Nlrp3 may be relevant biologically.
To determine whether cardiolipin was necessary for the
docking of Nlrp3 to the mitochondria, macrophages were incu-
bated with palmitate or control and then stimulated with silica
or linezolid. Macrophages were separated into mitochondrial
and cytosolic fractions and the location of Nlrp3 was determined
by immunoblot. Interference with cardiolipin synthesis through
palmitate treatment inhibited the stimulus-dependent associa-
tion of Nlrp3 with the mitochondria (Figure 6E), suggesting that
in addition to activating Nlrp3, cardiolipin is necessary for the
association of Nlrp3 with the mitochondria.
A critical step in the production of cardiolipin is the conversion
of phosphatidylglycerol to cardiolipin by the mitochondrial
enzyme cardiolipin synthase (CLS). In order to interfere with
cardiolipin by a separate approach, CLS was knocked down in
THP-1 cells with two different siRNA constructs with a resultant
51% and 48% decrease in CLS mRNA (Figure S4H). As ex-
pected, diminished CLS mRNA resulted in decreased cellular
cardiolipin as measured by thin-layer chromatography (Figures
S4I and S4J). Importantly, siRNA knockdown of CLS not only
lessened cardiolipin levels but also impaired the release of
IL-1b by THP-1 cells after stimulation with the ROS-dependent
Nlrp3 activators silica and ATP as well as the ROS-independent
activator linezolid (Figure 6F). Inhibition of CLS was specific to
IL-1b and did not inhibit the release of TNF-a (Figure 6F). In addi-
tion, although Nlrp3 inflammasome-dependent IL-1b release
was inhibited, activation of the AIM2 and Nlrc4 inflammasomes
remained intact after treatment with F. tularensis LVS and
P. aeruginosa, respectively (Figure 6F). Consistent with dimin-
ished IL-1b secretion in response to silica, ATP, and linezolid
after CLS siRNA treatment, we also observed a defect in
caspase-1 activation in CLS siRNA-treated cells specifically in
response to Nlrp3 agonists (Figure 6G). Together, these data
suggest themitochondrial lipid cardiolipin is specifically required
for Nlrp3 activation in response to both ROS-dependent and
ROS-independent activators.DISCUSSION
Mitochondria play a crucial role in orchestrating the activation of
the Nlrp3 inflammasome as evidenced by two studies showing
that the generation of ROSby themitochondrial respiratory chain
is required for Nlrp3 inflammasome activation (Nakahira et al.,
2011; Zhou et al., 2011). Our work identifies an Nlrp3 agonist
that does not rely on ROS as an intermediary for inflammasome
activation and suggests that Nlrp3 inflammasome activation is
mediated by sensing mitochondrial dysfunction through the
direct binding of Nlrp3 to the mitochondrial lipid cardiolipin.
The diverse molecules capable of activating the Nlrp3 inflam-
masome are structurally and biologically unrelated, making it
unlikely that they directly interact with Nlrp3. It is more likely
that these dissimilar agonists converge on a shared pathway
leading to Nlrp3 inflammasome activation. Steps in Nlrp3 inflam-
masome activation that are shared by all known activators
have until now included the efflux of potassium from the cell
(Pe´trilli et al., 2007) and the generation of mitochondrial ROS
(Nakahira et al., 2011; Zhou et al., 2011). However, we found
that ROS was dispensable for Nlrp3 inflammasome activation
in response to the oxazolidinone antibiotic linezolid, suggesting
that ROS generation is not an absolute requirement for Nlrp3
inflammasome activation as has been previously suggested.
We postulate that the events shared by ROS-dependent and
ROS-independent activators of the Nlrp3 inflammasome may
be mitochondrial destabilization and dysfunction, as indicated
by the fact that stabilization with cyclosporine A blocked all
Nlrp3 activators. In the case of ROS-dependent activators of
the Nlrp3 inflammasome, such as silica, ATP, and nigericin, it
may be that ROS contribute to mitochondrial dysfunction and
thereby indirectly promote Nlrp3 inflammasome activation.
Given that mitochondria are phylogenetically bacterial symbi-
onts of early eukaryotic cells and that cardiolipin is found only
in mitochondria and bacteria, it is attractive to postulate that
cardiolipin functions as an endogenous PAMP that is revealed
upon mitochondrial dysfunction and detected by Nlrp3. Disrup-
tion of macrophage cardiolipin synthesis by palmitate exposure
or siRNA knockdown of CLS resulted in specific defects in Nlrp3
(but not Nlrc4 or AIM2) inflammasome activation, suggesting
that cardiolipin plays a critical and selective role in Nlrp3 inflam-
masome activation. The requirement for cardiolipin in Nlrp3
inflammasome activation could be as a mitochondrial docking
site for inflammasome assembly and subsequent activation or
alternatively as the direct activating ligand for Nlrp3. Our studies
suggest that cardiolipin fulfills both roles, docking Nlrp3 at the
mitochondria as well as directly activating the inflammasome.
Apaf-1 can form a large multiprotein complex called the apop-
tosome, which is responsible for the activation of caspase-9 in
apoptosis. Parallels between the Nlrp3 inflammasome and the
apoptosome have been highlighted previously when it was noted
that low intracellular potassium is required for activation of the
apoptosome as well as for activation of the Nlrp3 inflammasome
(Cain et al., 2001; Tschopp, 2011). Additionally, interference
with the important mitochondrial membrane channel VDAC
not only inhibits apoptosis but also reduces Nlrp3 inflamma-
some-mediated IL-1b release (Zhou et al., 2011). Peroxidation
of cardiolipin results in the release of bound cytochrome c
into the cytosol where it binds to Apaf-1 (Garrido et al., 2006;Immunity 39, 311–323, August 22, 2013 ª2013 Elsevier Inc. 319
Figure 6. Cardiolipin Is Required and Sufficient for Nlrp3 Inflammasome Activation
(A) LPS-primed J774A.1 cells were lysed by nitrogen cavitation in the presence of liposomes containing phosphatidylcholine (300 mM), phosphatidylserine
(300 mM), phosphatidic acid (300 mM), or cardiolipin (300, 100, or 30 mM [left panel]; 300 mM [right panel]), incubated for 1 hr, and analyzed for caspase-1 and
GADPH by immunoblot.
(legend continued on next page)
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Nlrp3 Inflammasome Activation through CardiolipinKagan et al., 2005). Apaf-1 oligomerization forms the apopto-
some, which serves as a platform for caspase-9 activation
(Wang, 2001). Cardiolipin also plays an important role in the
extrinsic apoptotic pathway, because cardiolipin, after ROS-
dependent translocation to the outer mitochondrial membrane,
binds to caspase-8 and acts as a platform for its activation
(Gonzalvez et al., 2008). Hence, it appears that although multiple
apoptotic pathways converge on mitochondrial cardiolipin,
cardiolipin is also critical in the proinflammatory pathway of
Nlrp3 inflammasome activation. It remains unclear what factors
are required to induce Nlrp3 inflammasome activation without
additionally activating apoptosis, although our findings that
staurosporine can activate caspase-1 only if cells are first primed
suggests that a preceding inflammatory stimulus may provide
the signal for divergence. Alternatively, mitochondrial DNA has
been suggested to play a role in Nlrp3 inflammasome activation
(Nakahira et al., 2011; Shimada et al., 2012); it may be that
mitochondrial DNA in concert with cardiolipin serves as a regu-
lator in determining whether mitochondrial dysfunction will result
in Nlrp3 inflammasome activation, necrosis, or apoptosis.
EXPERIMENTAL PROCEDURES
Broken Cell System
LPS-primed J774A.1 cells were resuspended at 13 107 cells/ml in Dulbecco’s
phosphate-buffered saline (DPBS) (with Ca2+/Mg2+) supplemented with
25 mM KCl. For certain experiments, cells were pretreated with 0.5 mM palmi-
tate for 8 hr as above prior to priming. Cells were lysed by nitrogen cavitation as
previously described (Iyer et al., 2009), after which lysates were incubated at
37C for 1 hr in the presence of the indicated liposome and then analyzed
by SDS-PAGE and immunoblot. Liposomes were produced as previously
described (Iyer and Kusner, 1999). In brief, stock concentrations of each lipid
were made at 10 mMwith cardiolipin (Avanti Polar Lipids) in ethanol, phospha-
tidylcholine (Avanti Polar Lipids) in chloroform:methanol (2:1), phosphatidic
acid (Avanti Polar Lipids) in chloroform:methanol (2:1), or phosphatidylserine
(Sigma) in chloroform. Organic solvents were evaporated under nitrogen and
lipids were resuspended in DPBS and combined with phosphatidylcholine
(1:1 molar ratio), which served as the vehicle for the liposomes. Liposomes
were then sonicated with a probe sonicator for 10 min. Cardiolipin liposomes
were added at concentrations of 300, 100, or 30 mM; phosphatidylcholine lipo-
somes served as a negative control and were added at 300 mM.
Phospholipid Analysis
THP-1 and J774A.1 cells were labeledwith 6–10 mCi of 14C-linoleic acid (Perkin
Elmer) in RPMI for 24 hr. Unincorporated 14C-linoleic acid was washed away
and where noted cells were treated with palmitate for 20 hr. For phospholipid
analysis of hCLS1 siRNA-treated cells, 14C-linoleic acid labeling was per-
formed 48 hr after transfection with hCLS1 siRNA. Cells were harvested,
washed, and homogenized and lipids were extracted by the Bligh-Dyer
method (Bligh and Dyer, 1959) in the presence of 5mMHCl. The organic phase(B andC) J774A.1macrophages grown in the presence or absence of 0.5mMpalm
PAK strain (MOI 1:1). At 12 hr after stimulation, culture supernatants were collec
(D) J774A.1 macrophages grown in the presence or absence of 0.5 mM palmit
absence of 300 mM of cardiolipin liposomes. Lysates were incubated for 1 hr an
(E) J774A.1 cells grown in the presence or absence of 0.5 mM palmitate were LPS
cells were fractionated into mitochondrial and cytosolic fractions and subjected t
GAPDH (cytosolic marker).
(F andG) THP-1 cells treatedwith the indicated siRNAwere challengedwith linezo
(MOI 10:1) for 6 hr. Culture supernatants were collected and IL-1b and TNF-a relea
antibodies against pro-caspase-1 and the p20 subunit of caspase-1 (G).
Determinations were performed in triplicate and expressed as themean ± SD. Res
*p < 0.05, **p < 0.01, ***p < 0.005 by one-way ANOVA with Bonferroni’s multiplewas dried under nitrogen and equal amounts of radiolabeled lipids along with
standard phospholipids were applied to a 10 3 10 cm HP-TLC silica gel
60 plate (Merck). Phospholipids were resolved by 1-D TLC by the solvent
system chloroform:methanol:acetic acid::65:25:10 as described previously
(Choi et al., 2007; Koprivnjak et al., 2011).
Mitochondrial Isolation and Immunoprecipitation
Mitochondria were isolated from J774A.1 cells as previously described
(Iyer et al., 2009). For Nlrp3 immunoprecipitation, the mitochondrial fraction
was solubilized in 1% Triton X-100 containing lysis buffer and subjected to
immunoprecipitation with anti-mouse Nlrp3 antibody (Enzo) or isotype control
(IgG2b, Sigma). Lipids associated with the washed immunoprecipitates were
extracted with chloroform:methanol (2:1 v/v) and subjected to 1-D HP-TLC
as described above. Cytochrome c oxidase (COX) activity was assessed
with a COX assay kit (Sigma), wherein COX activity is represented as
decreased absorbance at 550 nM; inhibition of COX activity is represented
as a reduction in the decrease in absorbance (DA550). Untreated mitochondria
were treated with KCN (2.5 mM) as a positive control for COX inhibition.
Protein-Lipid Overlay Assay and Phospholipid-Coated Bead Assay
Binding of proteins to lipid strips (Echelon Biosciences) was performed
according to the manufacturer’s protocol. Strips were blocked in 3% fatty
acid-free BSA in TBS (25 mM Tris, 150 mM NaCl [pH 7.2]) followed by incuba-
tion with either column purified His-tagged constructs (10 mg/ml) or HA-tagged
constructs (5 mg/ml), or transiently transfected HEK293T lysates expressing
FLAG-tagged constructs in 1% fatty acid-free BSA in TBS for 8–16 hr at
4C. Strips were washed extensively in TTBS (0.05% Tween-20 in TBS) buffer
to remove unbound proteins. Bound proteins were detected by immuno-
blotting and ECL detection (Pierce).
Binding of proteins to phospholipid-coated beads (Echelon Biosciences)
was performed according to the manufacturer’s protocol. In brief, protein
(10 mg Ni column eluates) or cell lysates were diluted in binding buffer
(25 mM Tris, 150 mM NaCl [pH 7.2], 0.5% Triton X-100), added to a 50 ml sus-
pension of phospholipid-coated beads, and incubated for 8 hr at 4C. Beads
were washed extensively with binding buffer to remove unbound protein;
bound proteins were eluted by denaturing electrophoresis sample buffer and
subjected to polyacrylamide gel electrophoresis followed by immunoblotting
and ECL detection.
SUPPLEMENTAL INFORMATION
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